TNFRSF17 and plasma cell myeloma: Recently, antagonistic humanized anti-BCMA antibody-drug conjugates via a noncleavable linker with auristatins (monomethyl auristatin E, MMAE or monomethyl auristatin F, MMAF) in preclinical studies demonstrated impressive in vitro and in vivo anti-multiple myeloma activity [105,111].